Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 9Thoracic 5Dermatologic 5Head & Neck 4Gynecologic 2Gastrointestinal 2Breast 2Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 81Colorectal Neoplasms 39Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Liver Neoplasms 14Neoplasms 11Melanoma 11Carcinoma, Renal Cell 11Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Transitional Cell 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Head and Neck Neoplasms 7Cholangiocarcinoma 7Rectal Neoplasms 6Neoplasm Metastasis 6Colonic Neoplasms 6Urinary Bladder Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Merkel Cell 5Biliary Tract Neoplasms 5Prostatic Neoplasms 4Sarcoma 3Lung Neoplasms 3Gallbladder Neoplasms 3

Interventions

pembrolizumab 14Nivolumab 6Carboplatin 5sargramostim 4Fluorouracil 4Drug Therapy 4Thiotepa 3Sorafenib 3Radiotherapy 3Ipilimumab 3Interferon-alpha 3Gemcitabine 3Filgrastim 3Counseling 3Cetuximab 3liposomal doxorubicin 2ixabepilone 2entinostat 2cemiplimab 2belinostat 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Sirolimus 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Paclitaxel 2Methods 2Melphalan 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × atezolizumab × Gastrointestinal × Clear all
NCT03289962 2026-05-29

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Genentech, Inc.

Phase 1 Completed
273 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡